Clinical Trial Update: A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor [Phase 2]

View source ↗

Summary

This is a Phase II trial evaluating palbociclib for recurrent or refractory advanced thymic epithelial tumors; the current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Thymic Cancer | Phase 2 | Status: UNKNOWN